Earnings Live: Moderna & Snap Soar, Duolingo Dives

To be fair, if you’ve been watching the markets this week (November 2025), it feels like a proper high-stakes drama. We just saw three huge names—Moderna, Snap, and Duolingo—drop their results, and the reactions from investors couldn't have been more different.

​I’m telling you, this is exactly why I love earnings season. One minute you’re celebrating a massive comeback, and the next, you’re watching a top-tier app lose 30% of its value in a heartbeat. Let’s dive into why Moderna and Snap are currently the stars of the show, while Duolingo is left scratching its head.

​Moderna: the power of tightening the belt

​Let’s get into it—Moderna has been through a lot lately. With the pandemic in the rearview mirror, everyone was wondering how they’d keep the lights on. But on November 6, they dropped a revenue bomb of $1.02 billion. That’s significantly higher than the $800 million figure the “experts” were calling for.

​The thing is, it wasn't just about selling vaccines. The real reason the stock popped by over 8% was their massive cost-cutting. They’ve basically put the whole company on a diet. By slashing their 2025 spending and focusing only on the most important research, they showed investors that they know how to be responsible with their cash. I’m telling you, in a world where biotech companies often burn through money like water, seeing this kind of discipline is exactly what people wanted to see.

​Snap: AI is finally paying off

​Now, look at snap. For a while, people thought Snapchat was losing its edge, but their q3 numbers just proved everyone wrong. Revenue hit $1.51 billion, and their daily users jumped to 477 million. But the thing is, the numbers aren't what caused that massive 15% soar in the stock.

​It was the $400 million deal with Perplexity AI. I’m telling you, this is a game-changer. By bringing in advanced AI for their ads, Snap is telling the world that they aren't just a "filter app" anymore—they are a tech powerhouse. It’s the kind of move that makes a stock shoot up because it shows they have a plan for the future, not just the next few months. For Gen-Z users and advertisers, this partnership is a proper win-win.

​Duolingo: a tough lesson in forward-looking guidance

​. To be fair, this one is a bit of a heartbreaker. Duolingo’s Q3 was actually incredible. Their revenue was up 41%, and they hit over 50 million daily users. If you just looked at the past three months, they won big. But the stock still plunged by 30%. why?

​I’m telling you, the market doesn't care about what you did yesterday; it cares about what you’re doing tomorrow. Duolingo’s "guidance"—basically their prediction for the next few months—was a bit weak. They hinted that user growth might slow down a little, and that was enough to make everyone panic and sell. It’s a brutal reminder that in the world of edtech, you have to keep growing at a crazy speed, or the market will punish you. Even that cute green owl couldn't save them from this plunge.

​What can we learn from all this madness?

​The thing is, these three reports tell us a lot about where the market's head is at right now in late 2025. First, cost discipline is king. If you can show that you’re saving money like Moderna, people will trust you. Second, AI isn't just hype anymore; if you have a real partnership like Snap and Perplexity, the market will reward you.

​And finally, never underestimate the power of "guidance." You can have the best quarter in history, but if you sound even a little bit worried about the future (like Duolingo did), the investors will run for the hills. It’s a fast-paced game, and you have to stay sharp to survive.

​The road ahead for biotech and tech

​I’m telling you, the rest of 2025 is going to be very interesting. We’re seeing a big shift where companies are moving away from "growth at all costs" and moving toward "smart growth." Moderna is leading the way in biotech by narrowing its focus, and Snap is showing how social media can pivot to AI without losing its soul.

​Duolingo will likely bounce back—they have too many users to fail—but they’ve definitely been given a wake-up call. They need to show that their paid subscriptions can keep growing even if the free user growth slows down. For now, it’s all about watching who can innovate the fastest while keeping their bank balance in check.

​the final verdict

​At the end of the day, earnings season is about more than just numbers on a screen; it's about the story the company is telling. Moderna told a story of discipline, Snap told a story of innovation, and Duolingo, unfortunately,y told a story of caution. What’s your take? Are you buying the dip on Duolingo or riding the wave with Snap? let’s chat in the comments—this market doesn't wait for anyone, so you've got to make your move now!

​faq – stuff you actually want to know (no fluff)

​q: Why did Moderna's stock pop if vaccine sales are down?

To be fair, it’s all about the belt-tightening. Moderna slashed its future spending and showed it can be profitable even with lower sales. Investors love seeing a company that knows how to manage its cash.

​q: Is the snap and perplexity ai deal a big deal?

I’m telling you, it’s massive. It means Snap gets world-class AI to target its ads better, which means more money from advertisers. It’s why the stock soared 15%—it’s a huge vote of confidence in their future.

​q: Why did Duolingo drop so much if their users grew?

The thing is, the market felt their future predictions were too cautious. Even though they have 50 million users, investors got scared that the "boom" might be ending soon. It’s all about that forward-looking guidance.

​q: Should I buy the dip on Duolingo?

Let’s get into it—if you believe in their long-term plan, a 30% drop is a big discount. But keep in mind that the edtech space is getting crowded, so it’s definitely a bit of a gamble right now.